Recombinant Bovine Endoplasmic Reticulum-Golgi Intermediate Compartment Protein 3 (ERGIC3) is a protein involved in the trafficking between the endoplasmic reticulum (ER) and the Golgi apparatus. While specific information on the recombinant bovine version is limited, studies on human ERGIC3 provide valuable insights into its role and potential applications. ERGIC3 is known to play a significant role in cell proliferation and metastasis, particularly in cancer cells, where ER to Golgi trafficking is elevated .
ERGIC3 is part of the ER-Golgi intermediate compartment, which is crucial for protein modification, sorting, and transport. In cancer cells, enhanced ER to Golgi trafficking contributes to increased cell growth and epithelial-mesenchymal transition, leading to poor prognosis in lung cancer . Knockdown of ERGIC3 has been shown to induce ER stress, leading to autophagic cell death and suppression of proliferation in lung cancer cells .
Cell Proliferation and Metastasis: ERGIC3 promotes cell proliferation and metastasis in lung cancer. Its knockdown results in reduced cell growth and increased ER stress-induced autophagy .
Protein Interactions: ERGIC3 interacts with proteins involved in cytoskeleton construction and RHO GTPases activated p21-activated kinases, influencing cellular processes .
| Protein Type | Up-regulated | Down-regulated |
|---|---|---|
| Intracellular | 33 | 19 |
| Extracellular | 41 | 47 |
After ERGIC3 knockdown, significant changes in intracellular and extracellular proteins were observed, with extracellular proteins mainly involved in Ca²⁺ binding and transport, and intracellular proteins involved in histone methylation processes .
ERGIC3's role in cancer progression makes it a potential therapeutic target. Studies have shown that suppressing ERGIC3 can inhibit lung tumorigenesis, suggesting its utility in developing cancer therapies .
Function: Potentially involved in the transport of proteins between the endoplasmic reticulum and the Golgi apparatus.
KEGG: bta:509546
UniGene: Bt.6352
ERGIC3 functions as a cargo receptor in the early secretory pathway, participating in bidirectional protein trafficking between the ER and Golgi. It works in concert with other cargo receptors such as Surf4 and p25 to maintain the structural integrity of the ER-Golgi intermediate compartment (ERGIC) and Golgi apparatus .
Research indicates that ERGIC3 and related cargo receptors are essential for:
Stabilizing ERGIC membrane clusters
Mediating proper coat protein I (COPI) recruitment to membranes
Maintaining the architecture of the Golgi apparatus
The protein appears to be particularly important for maintaining the tubular-vesicular network structure of the ERGIC and the ribbon-like morphology of the Golgi complex.
For optimal stability and experimental reproducibility when working with recombinant bovine ERGIC3:
Reconstitution protocol:
Centrifuge the lyophilized protein vial briefly before opening
Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL
Add glycerol to a final concentration of 5-50% (50% is recommended)
Aliquot to minimize freeze-thaw cycles
Storage conditions:
Buffer composition:
Several imaging approaches have proven effective for studying ERGIC3 and the dynamic nature of the ERGIC compartment:
Live cell imaging with GFP fusion constructs:
Confocal laser scanning microscopy:
Quantification methodology:
When designing experiments, ensure proper controls to distinguish the ERGIC from the ER and Golgi compartments, as their proximity can complicate interpretation of results.
ERGIC3 knockdown produces significant structural and functional alterations:
| Parameter | Effect of ERGIC3 Knockdown | Measurement Method |
|---|---|---|
| ERGIC morphology | Reduced number of ERGIC clusters | Immunofluorescence with KDEL-receptor antibody |
| Golgi structure | Fragmentation into mini-stacks | Giantin staining |
| COPI localization | Partial redistribution to cytosol | β-COP immunostaining |
| ER stress | Increased | UPR marker expression analysis |
| Autophagy | Enhanced autophagic cell death | LC3 conversion assay |
| Cell proliferation | Suppressed (in cancer cells) | Growth curve analysis |
Mechanistically, ERGIC3 knockdown leads to ER stress-induced autophagic cell death in lung cancer cells, suggesting its potential as a therapeutic target . The structural effects are attributed to impaired COPI recruitment to membranes, which disrupts normal retrograde trafficking within the early secretory pathway .
Based on published research, several effective approaches for ERGIC3 knockdown include:
shRNA-mediated knockdown:
Short hairpin RNA targeting ERGIC3 (shERGIC3) has been successfully used
Can be delivered via lentiviral vectors for stable knockdown
For in vivo applications, non-invasive aerosol delivery using biocompatible carriers like glycerol propoxylate triacrylate and spermine (GPT-SPE) has proven effective
siRNA transient knockdown:
Validation methods:
When designing knockdown experiments, consider that simultaneous knockdown of multiple cargo receptors (e.g., ERGIC3 with Surf4 or p25) may produce more pronounced phenotypes due to functional redundancy in the early secretory pathway .
ERGIC3 has emerged as a significant factor in cancer biology, particularly in lung cancer:
Role in cancer progression:
Therapeutic targeting:
Mechanism of action:
This research suggests that ERGIC3 could be a promising target for developing novel lung cancer therapies, particularly through gene therapy approaches targeting its expression.
ERGIC3 functions within a network of cargo receptors that collectively maintain ERGIC and Golgi architecture:
Interaction partners:
Structural maintenance mechanisms:
Functional redundancy:
The research demonstrates that cargo receptors like ERGIC3 are not only important for specific cargo transport but also play structural roles that are critical for maintaining the integrity of the early secretory pathway.
When designing experiments to study ERGIC3 function, the following controls are essential:
For knockdown studies:
For localization studies:
For functional assays:
For in vivo studies:
Several technical challenges exist in studying ERGIC3, with potential solutions:
Distinguishing direct vs. indirect effects:
Functional redundancy among cargo receptors:
Dynamic nature of the ERGIC compartment:
Antibody specificity issues:
Physiological relevance of in vitro findings: